Instem PLC (LON:INS)

Instem PLC (LON:INS)

Share Price
369.00 p
9 (2.50 %)
Market Cap
£60.14 m
Proactive Investors - Run By Investors For Investors

Instem PLC

We help our over 500 international clients efficiently access, capture, analyze, report and submit high quality regulatory data, while maintaining compliance for their products around the world. This is combined with our unique ability to generate new knowledge through the extraction and harmonization of public and proprietary sources of actionable scientific information.


Market: AIM:INS
52-week High/Low: 390.000p / 174.600p
Sector: Software & Computer Services
Market Cap: £60.14 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Instem PLC

Instem PLC Snapshot

For the more than 500 clients around the world, we are supplying breakthrough technology and services that help them efficiently access, capture, manage and enrich a wide array of data while generating new insight to advance their mission.

Instem clients experience measurable benefits such as:

  • Greater confidence in the safety and efficacy of their product portfolio
  • Shorter R&D cycles with reduced costs
  • Better management controls
  • Increased regulatory compliance
  • More effective resource utilization with greater staff satisfaction
  • Happier and healthier clinical subjects
  • Enhanced care and reduction of animal usage

Phil Reason*
Chief Executive Officer

Phil has been leading Instem as CEO since 1995, working closely with the Instem Board, investors, management, clients, partners and staff to grow the business from a single product line with fifteen clients to serving hundreds of customers as the global market leader across a wide area of life sciences R&D.  Passionate about Instem’s ability to support clients in introducing transformational approaches for life changing therapies, Phil has been a vocal advocate of long-term partnerships, innovative organic growth, geographic expansion and the acquisitive consolidation of the fragmented IT supplier community. Under Phil’s leadership Instem has completed the strategic acquisition of 7 companies, has opened new offices in the US, UK, China, and India and has completed a UK-based IPO in 2010.

Gordon Baxter BSc, PhD
Chief Scientific Officer 

A pharmacologist, Gordon has held several senior discovery positions in major pharmaceutical companies and was a founding entrepreneur of the CRO, Pharmagene plc. and held positions of Chief Scientific Officer and Chief Operating Officer. He was also a founder of the UK-based healthcare intelligence company, BioWisdom Ltd which was acquired by Instem in 2011. He has a track record of innovation in drug discovery and has contributed to the development of several marketed drugs. He is an advocate of Translational Informatics; using data gathered from research, development and medical practice to generate new therapeutic insights. Gordon is on the Board of the R&D information technology group, the Pistoia Alliance.

Vince D’Angelo 
Vice President, Global Quality Assurance

Vince is responsible for Instem’s ISO9001 certification and oversees quality at all Instem office locations around the world for all product lines.  Vince has been with Instem since 1988 having had roles in software development and computer systems validation. He has developed processes that have successfully passed inspection by regulatory bodies and has been at the forefront in the use of automated test tools to provide regression testing and qualification evidence.
Vince is a Fellow of the Research Quality Association (RQA), an active member of the Society of Quality Assurance (SQA) and regularly gives presentations at their annual conferences and is the past Chair of the SQA Computer Validation, Information technology, Compliance (CVIC) specialty section which currently has members from many of today’s leading Pharmaceutical companies and contract research organizations.

Nigel Goldsmith*
Chief Financial Officer

Nigel joined Instem in November of 2011 and possesses a wealth of experience in senior financial roles at both public and private companies within the life sciences industry. Prior to Instem, Nigel was Finance Director for 3 years at the AIM listed, pharmaceutical and medical devices company, IS Pharma plc. He also held the position of CFO for 7 years at Almedica International Inc., a privately held supplier of clinical trial materials to the global pharmaceutical and biotech markets and 2 years as European Controller for the sales and marketing division of laboratory equipment manufacturer, Life Sciences International plc. Prior to entering industry, Nigel spent over 9 years at KPMG and is a qualified Chartered Accountant.

Mick Davison
Vice President, Software Development

Mick leads a highly skilled, multidisciplinary software development group based across various locations in Europe, North America and India. He is responsible for setting and driving the strategy for software architecture, development, security, testing and certification, while also ensuring the continued delivery of high quality product offerings across all of Instem’s markets.
Drawing on his extensive technical skills and leadership qualities, Mick has established a harmonized software development group comprising in-house and outsourced resources, which encompasses Software Development, Software Test, Database Administration, Build & Release, Architecture and Validation. 
Since joining Instem in February 2017, Mick has helped to develop a compelling technical vision, providing clear leadership and direction in the development and delivery of functionally rich, high quality, secure software applications for Instem’s worldwide customer base.

Jerry Hacker
Senior Vice President, Global Sales

Jerry joined Instem in 2016 and is responsible for managing a strong, global sales team to help maximize Instem’s market share around the world, while also opening up new market segments. 
Jerry’s formidable solution-oriented sales leadership skills, combined with his passion for excellence and his drive for continuous improvement, have helped Instem to develop new geographic and vertical markets and drive revenue growth, while greatly increasing productivity and performance of the sales team. Jerry has held several executive-level leadership roles within health & life sciences over the past 25 years, where he has successfully built and led high performing software and consulting services sales teams and partner programs. Prior to joining Instem, Jerry was SVP Worldwide Sales at LabVantage Solutions, where he helped drive record revenue growth for their Laboratory Information Management Systems.

Adrian Gare
Vice President, Corporate Development

Supporting Instem’s strategy to identify suitable acquisition and partnership opportunities to help consolidate and empower the R&D IT community, Adrian is responsible for sourcing and transacting key strategic projects around the world. Adrian’s accomplishments include Instem’s acquisitions of BioWisdom, Logos Technologies and Perceptive Instruments and he is involved in collaborative licensing agreements and joint ventures. Adrian is a qualified chartered accountant with over 15 years of experience in corporate finance and M&A activities and has a proven track record of success with a Top-10 firm of accountants.

Gregor Grant
Executive Vice President, Preclinical Solutions

Gregor is an experienced leader with a proven track record of success in developing customer relationships and delivering IT solutions for the Life Sciences Industry. Gregor is passionate about ensuring the exceptional client experience and his team provides development, deployment and support services to Instem’s Preclinical Solutions clients around the world, including products from the acquisition of Perceptive Instruments in 2013. Gregor joined Instem through an acquisition of Apoloco in 1996, a smaller competitor specializing in pathology solutions.  For over 20 years Gregor has been instrumental in helping create both a successful software product, and building a reputation for high quality and service within a passionate and demanding user community.   

Mike Harwood 
Executive Vice President, Regulatory eStudy Solutions

Mike joined Instem in 1999 through the acquisition of Fraser Williams Data Systems where he was a Director overseeing Client Services.  While most of Mike’s more recent experience has been in the deployment of regulatory preclinical solutions, since 1977 he has worked on applications across the R&D continuum from early stage chemical databases to late stage clinical trials systems. Mike joined the SEND standard development team back in 2003 providing key input and was pivotal in bringing the first commercial SEND software solution to market in 2005. Mike now leads a team of industry experts supporting the most comprehensive and widely deployed set of tools and services for SEND in today’s global marketplace.

Gary Mitchell
Vice President, Global Marketing

Gary leads an international team responsible for the development of programs that help generate demand for Instem’s software solutions and services. He helps create and carry out our strategic growth plans by positioning and promoting Instem as the global leader of technologies that empower mission critical R&D programs to introduce better drugs, therapies & products more quickly. For more than 20 years Gary has held key management positions where he has developed high-impact B2B marketing programs & processes and is well versed in strategic market planning, new product branding and launches. Prior to joining Instem in May of 2004, Gary was a Senior Marketing Specialist with Dun & Bradstreet focused on creating and executing business development and go-to-market programs for its B2B Sales & Marketing products.

Gwen Aston
Senior Vice President, Instem Clinical

Gwen joined Instem in 2014 after having worked in the clinical space for 30 years. She has a wealth of experience in clinical pharmacology and clinical research, along with a proven eSource system deployment track record. Gwen’s extensive experience includes running a number of Phase I sites and clinics for large pharmaceutical and contract research organizations, as well as smaller independent sites. Gwen has additionally managed successful global implementation projects and is well respected throughout commercial industry and within regulatory agencies.
Gwen heads up Instem Clinical, Instem’s early phase clinical study management business, which has been at the forefront of early phase clinical trials for over a decade. Prior to joining Instem, Gwen was Senior Director & General Manager of Clinical Pharmacology at ICON Development Solutions.

MaryBeth Thompson 
Chief Operating Officer

MaryBeth has over 18 years’ life sciences industry experience, with a primary focus in Regulatory Affairs and Operations. She is a proven leader in developing and optimizing outsourcing services businesses and has a strong track record in customer facing leadership. 
In her role as COO, MaryBeth oversees strategy, planning, development and management of Instem’s Global Operations team to meet client demand, while driving Instem’s commitment to delivering an exceptional client experience. At Instem, MaryBeth has been instrumental in delivering key process improvements, implementing best-in-class solutions, raising quality and improving operations department productivity.
Prior to joining Instem in 2017, MaryBeth was VP Global Regulatory Services at life sciences consulting firm PARAXEL International, where she established and grew a 30-person regulatory outsourcing consultancy into a full global practice of 300 staff.

*Board member

Director Shareholdings

Director Name Amount % Holding
David Sherwin 1,380,066 8.5%
David Gare 1,158,427 7.1%
Phil Reason 685,287 4.2%
Mike McGoun 36,786 0.2%
Total 3,260,566 20.0%


USA Headquarters

610 941 0990

UK Headquarters

+44 (0) 1785825600

GeneTox Solutions

+44 (0) 1284 765566

Office Address

Diamond Way
Stone Business Park
Stone, Staffordshire
ST15 0SD
United Kingdom


Financial Advisor, NOMAD and Broker N+1 Singer
One Bartholomew Lane

Lawyers Squire Patton Boggs (UK) LLP
Trinity Court
16 John Dalton Street
M60 8HS

Reporting Accountants RSM Corporate Finance LLP
3 Hardman Street
M3 3HF

Auditors RSM UK Audit LLP
3 Hardman Street
M3 3HF

Registrars Computershare Investor Services PLC
Bridgwater Road
BS13 8AE

Financial PR Walbrook PR Limited
4 Lombard Street

Banker National Westminster Bank Plc
1 Spinningfields Square
M3 3AP

UK Headquarters

Tel: +44 (0) 1785 825600

US Headquarters

Tel: +1 610.941.0990

Instem plc Registered Office

Diamond Way
Stone Business Park
ST15 0SD
United Kingdom

Columns Including INS


Market Reports Including INS

Video RSS



© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use